ProfNoel G McElvaney
Head Of School Of Medicine
Department of Medicine
- Head Of School Of MedicineDepartment of Medicine
RESEARCH OVERVIEW
Protease/anti protease interactions in the lungSignal transduction in bronchial epitheliumInnate defenses of the lungGene therapy for lung diseases
GRANTS
- FUNDED PROJECTClimate and Lung Early Alert Response in GENetically vulnerable populationsEnterprise Ireland30 Jun 2026 - 29 Jun 2028
- FUNDED PROJECTAlpha-1 Foundation Ireland Research funds 2026Alpha-1 Foundation (Ireland)1 Jan 2026 - 31 Dec 2026
- FUNDED PROJECTMZ AATDPrivate Donor1 Jan 2026 - 31 Jan 2029
- FUNDED PROJECTClinical Nurse Manager (CNM) for Clinical TrialsPrivate Donor10 Dec 2025 - 31 Dec 2026
- FUNDED PROJECTTAK-999-3001: Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 FibrosisIndustry - Sponsored Clinical Trial – Economic Activity6 Nov 2025 - 5 Nov 2027
- FUNDED PROJECTBEAM - A Phase 1/2 Dose-Exploration and Dose-Expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients with Alpha-1 Antitrypsin Deficiency (AA TD)-Associated Lung Disease and/or Liver DiseaseIndustry - Sponsored Clinical Trial – Economic Activity22 Oct 2025 - 21 Oct 2027
- FUNDED PROJECTTAK-999-3002: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 FibrosisIndustry - Sponsored Clinical Trial – Economic Activity22 Oct 2025 - 21 Oct 2027
- FUNDED PROJECTTAK-999-5008: Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver DiseaseIndustry - Sponsored Clinical Trial – Economic Activity22 Oct 2025 - 21 Oct 2033
- FUNDED PROJECTLung Immune Cell Outcomes in AATD supportPrivate Donor6 Oct 2025 - 5 Oct 2026
- FUNDED PROJECTAlpha-1 Foundation Ireland laptopPrivate Donor1 Oct 2025 - 30 Sep 2026
- FUNDED PROJECTRare Bronchiectasis Diseases Consortium (RBDC)National Institute for Health (NIH) US15 Sep 2025 - 31 May 2030
- FUNDED PROJECTRespiratory Research RE LBPrivate Donor4 Aug 2025 - 3 Aug 2027
- FUNDED PROJECTRespiratory Research - Lucy KirwanPrivate Donor17 Jul 2025 - 31 Dec 2028
- FUNDED PROJECTRespiratory Research RE S RochePrivate Donor14 Jul 2025 - 10 Jul 2026
- FUNDED PROJECTComprehensive Lipidomic Profiling of Bronchoalveolar Lavage Fluid (BALF) in AATDAlpha-1 Foundation (US)1 Jul 2025 - 30 Jun 2026
- FUNDED PROJECTA Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AA TD) EmphysemaIndustry - Sponsored Clinical Trial – Economic Activity28 Apr 2025 - 2 Apr 2028
- FUNDED PROJECTPhase 1/2 Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-3001 in Participants with Alpha-1 Antitrypsin Deficiency (AATD)- Associated Lung DiseaseIndustry – Company Sponsored Clinical Trial10 Mar 2025 - 9 Mar 2026
- FUNDED PROJECTStAR MD Programme 2025RCSI1 Mar 2025 - 31 Oct 2027
- FUNDED PROJECTAlpha-1 Foundation Ireland Research fundsAlpha-1 Foundation (Ireland)1 Jan 2025 - 31 Dec 2025
- FUNDED PROJECTThe Risk of Lung Disease in People with MZ Alpha-1 Antitrypsin Deficiency.Alpha-1 Foundation (US)1 Jan 2025 - 31 Dec 2027
- FUNDED PROJECTA Detailed Study of Lung Immune Cell Outcomes in AATDAlpha-1 Foundation (US)1 Jul 2024 - 31 Dec 2026
- FUNDED PROJECTA Study of the Sustained Effect of Elexacaftor/Tezacaftor/Ivacaftor on Airway and Systemic Inflammation in People with Cystic FibrosisCystic Fibrosis Foundation1 Feb 2024 - 14 Oct 2026
- FUNDED PROJECTAdministration of patient questionnaire to existing AATD population, and analysis of resulting dataIndustry15 Jan 2024 - 30 Jun 2026
- FUNDED PROJECTRespiratory Research Lab CoordinatorPrivate Donor15 Dec 2023 - 15 Dec 2025
- FUNDED PROJECTCollaborative Initiative 2023/24RCSI1 Sep 2023 - 28 Feb 2025